Ribas A, Wolchok JD. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol. 2013;25(2):291–6. https://doi.org/10.1016/j.coi.2013.02.011.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science. 1995;270(5238):932–3. https://doi.org/10.1126/science.270.5238.932.

Article  CAS  PubMed  Google Scholar 

Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765–72. https://doi.org/10.1093/intimm/8.5.765.

Article  CAS  PubMed  Google Scholar 

Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34. https://doi.org/10.1084/jem.192.7.1027.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolchok JD, Hodi FS, Weber JS, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291(1):1–13. https://doi.org/10.1111/nyas.12180.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64. https://doi.org/10.1016/s1470-2045(09)70334-1.

Article  CAS  PubMed  Google Scholar 

Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44. https://doi.org/10.1056/NEJMoa1305133.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in Patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12. https://doi.org/10.1200/jco.2014.58.3708.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. https://doi.org/10.1056/NEJMoa1503093.

Article  CAS  PubMed  Google Scholar 

Larkin J, Minor D, D’Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36(4):383–90. https://doi.org/10.1200/jco.2016.71.8023.

Article  CAS  PubMed  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56. https://doi.org/10.1056/NEJMoa1709684.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. https://doi.org/10.1056/NEJMoa2109970.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. https://doi.org/10.1038/nature00766.

Article  CAS  PubMed  Google Scholar 

Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16(6):345–58. https://doi.org/10.1038/nrc.2016.37.

Article  CAS  PubMed  Google Scholar 

Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239–71. https://doi.org/10.1146/annurev-pathol-012513-104658.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455–67. https://doi.org/10.1038/nrc3760.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30(20):2522–9. https://doi.org/10.1200/jco.2011.41.2452.

Article  PubMed  Google Scholar 

Kiuru M, Busam KJ. The NF1 gene in tumor syndromes and melanoma. Lab Investig. 2017;97(2):146–57. https://doi.org/10.1038/labinvest.2016.142.

Article  CAS  PubMed  Google Scholar 

Rabbie R, Ferguson P, Molina-Aguilar C, Adams DJ, Robles-Espinoza CD. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. J Pathol. 2019;247(5):539–51. https://doi.org/10.1002/path.5213.

Article  PubMed  PubMed Central  Google Scholar 

Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175–80. https://doi.org/10.1038/nature22071.

Article  CAS  PubMed  Google Scholar 

Newell F, Johansson PA, Wilmott JS, et al. Comparative genomics provides etiologic and biological insight into melanoma subtypes. Cancer Discov. 2022;12(12):2856–79. https://doi.org/10.1158/2159-8290.Cd-22-0603.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeh I, Jorgenson E, Shen L, et al. Targeted genomic profiling of acral melanoma. J Natl Cancer Inst. 2019;111(10):1068–77. https://doi.org/10.1093/jnci/djz005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pham DDM, Guhan S, Tsao H. KIT and melanoma: biological insights and clinical implications. Yonsei Med J. 2020;61(7):562–71. https://doi.org/10.3349/ymj.2020.61.7.562.

Article  CAS  PubMed  Google Scholar 

Yeh I, Bastian BC. Melanoma pathology: new approaches and classification. Br J Dermatol. 2021;185(2):282–93. https://doi.org/10.1111/bjd.20427.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moran JMT, Le LP, Nardi V, et al. Identification of fusions with potential clinical significance in melanoma. Mod Pathol. 2022;35(12):1837–47. https://doi.org/10.1038/s41379-022-01138-z.

Article  CAS  PubMed  Google Scholar 

Yen I, Shanahan F, Lee J, et al. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature. 2021;594(7863):418–23. https://doi.org/10.1038/s41586-021-03515-1.

Article  CAS  PubMed  Google Scholar 

de Braud F, Dooms C, Heist RS, et al. Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: results from the expansion arm of a phase Ib, open-label study. J Clin Oncol. 2023;41(14):2651–60. https://doi.org/10.1200/jco.22.02018.

Article  PubMed  Google Scholar 

Lebbe C. LBA40 Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma. Ann Oncol. 2022;33(7):S1407.

Article  Google Scholar 

Sullivan RJ, Infante JR, Janku F, et al. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov. 2018;8(2):184–95. https://doi.org/10.1158/2159-8290.Cd-17-1119.

Article  CAS  PubMed  Google Scholar 

Tarin M, Némati F, Decaudin D, et al. FAK inhibitor-based combinations with MEK or PKC inhibitors trigger synergistic antitumor effects in uveal melanoma. Cancers. 2023. https://doi.org/10.3390/cancers15082280.

Article  PubMed  PubMed Central  Google Scholar 

Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016;45:129–38. https://doi.org/10.1016/j.ctrv.2016.03.002.

Article